Cryo-Save director stocks up on shares
A round-up of the biggest director deals today so far.
Werner Spinner, a non-executive director at the stem cell bank group Cryo-Save, has topped up his stake in the company, taking about £20,000 worth of shares.
Spinner, who served for 30 years with the German drug giant Bayer, took 25,000 shares at 77.2p a time.
He now has 284,868 shares or about 0.6% of Cryo-Save.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Cryo-Save, which has its headquarters in the Netherlands and stores more than 100,000 adult stem cells in storage facilities in Belgium, Germany and Dubai, last month reported a fall in full-year profits due to higher operating expenses, but said it was well positioned to capitalise on its international position.
Revenue was up 67% to €29.5m in the year ended 31 December, while pre-tax profit fell to €2.86m compared with €4.51m last time as operating expenses rose to €17.9m from €7.13m previously.
Top Director Buys
Value: £49,980
Value: £19,740
Value: £19,300
Value: $12,000
Value: £10,183
Top Director Sells
Value: £2,400,000
Value: £2,400,000
Value: £960,000
Value: £321,922
Value: £119,138
Value: £53,472
Value: £41,736
Value: £38,244
Value: £35,123
Value: £12,000
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Trump wants to colonise Mars – will it happen?
Donald Trump wants to plant the US flag on Mars. Could humans really live there?
By Simon Wilson
-
Klarna postpones US IPO as Trump's tariffs rattle markets
Buy-now-pay-later lender Klarna has postponed its US initial public offering owing to the market turbulence. It is not alone, says Matthew Partridge
By Dr Matthew Partridge